{"nctId":"NCT01830543","briefTitle":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","startDateStruct":{"date":"2013-05-10","type":"ACTUAL"},"conditions":["Atrial Fibrillation","Percutaneous Coronary Intervention"],"count":2124,"armGroups":[{"label":"rivaroxaban 2.5 mg twice daily","type":"EXPERIMENTAL","interventionNames":["Drug: rivaroxaban 2.5 mg","Drug: rivaroxaban 15 mg","Drug: rivaroxaban 10 mg","Drug: aspirin (ASA)","Drug: clopidogrel","Drug: prasugrel","Drug: ticagrelor"]},{"label":"vitamin K antagonist (VKA)","type":"EXPERIMENTAL","interventionNames":["Drug: aspirin (ASA)","Drug: vitamin K antagonist (VKA)","Drug: clopidogrel","Drug: prasugrel","Drug: ticagrelor"]},{"label":"rivaroxaban 15 mg once daily","type":"EXPERIMENTAL","interventionNames":["Drug: rivaroxaban 15 mg","Drug: rivaroxaban 10 mg","Drug: clopidogrel","Drug: prasugrel","Drug: ticagrelor"]}],"interventions":[{"name":"rivaroxaban 2.5 mg","otherNames":[]},{"name":"rivaroxaban 15 mg","otherNames":[]},{"name":"rivaroxaban 10 mg","otherNames":[]},{"name":"aspirin (ASA)","otherNames":[]},{"name":"vitamin K antagonist (VKA)","otherNames":[]},{"name":"clopidogrel","otherNames":[]},{"name":"prasugrel","otherNames":[]},{"name":"ticagrelor","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a documented medical history of paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF)\n* Have undergone percutaneous coronary intervention (PCI) procedure (with stent placement) for primary atherosclerotic disease\n* Must have an international normalized ratio (INR) of 2.5 or below to be randomized\n* Women must be postmenopausal before entry or practicing a highly effective method of birth control when heterosexually active\n* Be willing and able to adhere to the prohibitions and restrictions specified in the study protocol\n\nExclusion Criteria:\n\n* Have any condition that contraindicates anticoagulant or antiplatelet therapy or would have an unacceptable risk of bleeding, such as, but not limited to: platelet count \\<90,000/microliter at screening, history of intracranial hemorrhage, 12 month history of clinically significant gastrointestinal bleeding, non-VKA induced elevated prothrombin time (PT) at screening\n* Have anemia of unknown cause with a hemoglobin level \\<10 g/dL (\\<6.21 mmol/L)\n* Have a history of stroke or Transient Ischemic Attack (TIA)\n* Have a calculated Creatinine Clearance (CrCl) \\<30 mL/min at screening\n* Have known significant liver disease or liver function test (LFT) abnormalities\n* Have any severe condition that would limit life expectancy to less than 12 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Clinically Significant Bleeding","description":"Clinically significant bleeding is a composite of Thrombolysis in Myocardial Infarction (TIMI) major bleeding, minor bleeding, and bleeding requiring medical attention (BRMA). TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of greater than or equal to (\\>=) 5 grams per deciliter (g/dL) (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of \\>=15 percent (%)). TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to less than (\\<) 5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to \\<15 percent). A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null},{"groupId":"OG001","value":"16.6","spread":null},{"groupId":"OG002","value":"24.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Major Bleeding","description":"TIMI major bleeding is defined as any symptomatic intracranial hemorrhage, Clinically overt signs of hemorrhage (including imaging) associated with a drop in hemoglobin of \\>= 5 g/dL (or when the hemoglobin concentration is not available, an absolute drop in hematocrit of \\>=15 percent).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"1.7","spread":null},{"groupId":"OG002","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"2.8","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"1.1","spread":null},{"groupId":"OG002","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Thrombolysis in Myocardial Infarction (TIMI) Minor Bleeding","description":"TIMI minor bleeding event is defined as any clinically overt sign of hemorrhage (including imaging) that is associated with a fall in hemoglobin concentration of 3 to \\<5 g/dL (or, when hemoglobin concentration is not available, a fall in hematocrit of 9 percent to \\<15 percent).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.0","spread":null},{"groupId":"OG002","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"0.4","spread":null},{"groupId":"OG002","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"1.4","spread":null},{"groupId":"OG002","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Bleeding Requiring Medical Attention (BRMA)","description":"A BRMA event is defined as any bleeding event that requires medical treatment, surgical treatment, or laboratory evaluation, and does not meet criteria for a major or minor bleeding event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"14.4","spread":null},{"groupId":"OG002","value":"19.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"16.7","spread":null},{"groupId":"OG002","value":"18.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"12.9","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"14.9","spread":null},{"groupId":"OG002","value":"18.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Composite of Adverse Cardiovascular Events (Cardiovascular Death, Myocardial Infarction (MI) and Stroke)","description":"Percentage of participants who experienced adverse cardiovascular events (cardiovascular death, myocardial Infarction (MI) and stroke) collectively, were assessed.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"5.1","spread":null},{"groupId":"OG002","value":"5.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"5.6","spread":null},{"groupId":"OG002","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"6.5","spread":null},{"groupId":"OG002","value":"3.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"6.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Cardiovascular Death","description":"The percentage of participants with the first occurrence of cardiovascular death were evaluated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"1.7","spread":null},{"groupId":"OG002","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Myocardial Infarction","description":"The percentage of participants with the first occurrence of Myocardial Infarction were evaluated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"2.8","spread":null},{"groupId":"OG002","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"2.8","spread":null},{"groupId":"OG002","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Stroke","description":"The percentage of participants with the first occurrence of Stroke were evaluated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"1.4","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"2.4","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"1.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Stent Thrombosis","description":"The percentage of participants with the first occurrence of stent thrombosis were evaluated.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"0.9","spread":null},{"groupId":"OG002","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"1.9","spread":null},{"groupId":"OG002","value":"0.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"1.6","spread":null},{"groupId":"OG002","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":237,"n":696},"commonTop":["Epistaxis","Haematoma","Contusion","Dyspnoea","Gingival Bleeding"]}}}